Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,642,492
  • Shares Outstanding, K 155,861
  • Annual Sales, $ 339,080 K
  • Annual Income, $ -235,260 K
  • 60-Month Beta 1.80
  • Price/Sales 25.77
  • Price/Cash Flow N/A
  • Price/Book 13.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.44
  • Number of Estimates 8
  • High Estimate -0.36
  • Low Estimate -0.50
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.46 +24.73%
on 06/12/20
58.72 -5.57%
on 07/07/20
+8.43 (+17.93%)
since 06/10/20
3-Month
42.07 +31.81%
on 04/13/20
58.72 -5.57%
on 07/07/20
+11.65 (+26.60%)
since 04/09/20
52-Week
21.56 +157.19%
on 07/23/19
58.72 -5.57%
on 07/07/20
+28.15 (+103.11%)
since 07/10/19

Most Recent Stories

More News
NASDAQ, S&P End 5-Day Winning Streaks

NASDAQ, S&P End 5-Day Winning Streaks

MSFT : 213.67 (-0.30%)
GPC : 85.58 (+1.34%)
SNBR : 52.97 (+13.18%)
STZ : 184.93 (+1.39%)
BBBY : 8.19 (+4.26%)
SOI : 6.90 (+1.62%)
THO : 101.85 (+4.62%)
SQQQ : 6.18 (-2.22%)
UNFI : 19.31 (-1.68%)
IAC : 127.49 (+2.11%)
RHP : 31.45 (+1.94%)
LVS : 45.72 (+2.33%)
HTHT : 36.55 (-2.22%)
RDS.A : 32.21 (+2.97%)
AYX : 178.02 (-2.18%)
MPC : 36.20 (+8.55%)
NEO : 35.85 (-1.27%)
STNE : 39.84 (-3.95%)
TJX : 51.07 (+2.16%)
TWTR : 35.40 (-0.90%)
XYL : 66.51 (-0.02%)
BLUE : 63.99 (-3.28%)
CRSP : 89.47 (-4.84%)
SGMO : 10.69 (-1.84%)
NTLA : 23.81 (-3.09%)
ACAD : 55.45 (-1.11%)
ALNY : 162.25 (+2.02%)
EDIT : 32.88 (-4.68%)
Dow Surges 2.3% as Boeing Begins Testing the 737 Max

Dow Surges 2.3% as Boeing Begins Testing the 737 Max

MGY : 6.35 (+4.79%)
CIEN : 54.97 (-2.12%)
INSG : 11.24 (-1.58%)
KMX : 88.19 (+2.27%)
MSM : 64.64 (+0.65%)
LPX : 26.99 (+4.45%)
HLF : 45.64 (+0.22%)
LEN : 65.26 (+3.18%)
CMC : 19.94 (+4.07%)
DIN : 37.69 (+6.26%)
PSX : 61.06 (+3.53%)
ACAD : 55.45 (-1.11%)
AXLA : 5.09 (-0.97%)
BA : 178.44 (+2.98%)
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

LGND : 115.06 (+2.54%)
ACAD : 55.45 (-1.11%)
AKCA : 13.01 (-2.11%)
NCNA : 5.31 (+3.31%)
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID(R) (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new...

ACAD : 55.45 (-1.11%)
Why Is Acadia (ACAD) Down 7.6% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACAD : 55.45 (-1.11%)
Depression Screening Market Business Growth Analysis with Top Players: Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc., Medtronic, Meiji Holdings Company, Ltd., Bristol-Myers Squibb Company Considering COVID-19 Impact

The latest Depression Screening Market study by Data Bridge Market Research offers an all-inclusive, in-depth analysis of the major strategies, corporate models, and market shares of the prominent players...

ACAD : 55.45 (-1.11%)
BMY : 57.43 (-1.17%)
MDT : 90.81 (+0.75%)
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020, at 4:40 p.m. Eastern Time.

ACAD : 55.45 (-1.11%)
Neurodegenerative Diseases Drugs Market to Exhibit 7.2% CAGR till 2026; Rising Geriatric Population to Aid Growth: Fortune Business Insights(TM)

The global neurodegenerative diseases drugs market is likely to gain traction from the rising incidence of neurodegenerative diseases worldwide. Such diseases pose a greater burden on the physical and...

ACAD : 55.45 (-1.11%)
MRK : 76.73 (+0.05%)
MTZPY : 18.6000 (-0.13%)
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business...

ACAD : 55.45 (-1.11%)
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.

HALO : 27.90 (-0.34%)
ACAD : 55.45 (-1.11%)
XENE : 13.22 (-0.68%)
AKCA : 13.01 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACAD with:

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

2nd Resistance Point 56.98
1st Resistance Point 56.22
Last Price 55.45
1st Support Level 54.89
2nd Support Level 54.32

See More

52-Week High 58.72
Last Price 55.45
Fibonacci 61.8% 44.52
Fibonacci 50% 40.14
Fibonacci 38.2% 35.76
52-Week Low 21.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar